You are here: All Products  > CBT Acquires Global Rights to CTLA-4 Checkpoint Inhibitor in $46 Million Deal

CBT Acquires Global Rights to CTLA-4 Checkpoint Inhibitor in $46 Million Deal

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products